Personalis (NASDAQ:PSNL) Earns “Buy” Rating from Needham & Company LLC

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating restated by Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $3.50 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 123.64% from the stock’s previous close.

Separately, Lake Street Capital began coverage on shares of Personalis in a report on Tuesday, April 30th. They issued a “buy” rating and a $4.00 price target on the stock.

Personalis Stock Down 0.9 %

NASDAQ:PSNL opened at $1.57 on Thursday. The business’s 50-day simple moving average is $1.48 and its two-hundred day simple moving average is $1.45. Personalis has a 52 week low of $0.89 and a 52 week high of $2.60. The stock has a market cap of $79.03 million, a PE ratio of -0.70 and a beta of 1.91.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. The company had revenue of $19.68 million for the quarter, compared to analysts’ expectations of $19.56 million. Sell-side analysts anticipate that Personalis will post -1.58 earnings per share for the current fiscal year.

Institutional Trading of Personalis

A number of large investors have recently added to or reduced their stakes in PSNL. Howland Capital Management LLC grew its holdings in shares of Personalis by 392.8% in the first quarter. Howland Capital Management LLC now owns 211,118 shares of the company’s stock valued at $315,000 after purchasing an additional 168,274 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of Personalis by 6.2% in the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after buying an additional 24,498 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Personalis by 11.3% during the 1st quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock valued at $736,000 after buying an additional 50,000 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Personalis in the 4th quarter valued at about $152,000. Finally, Bruce & Co. Inc. grew its position in Personalis by 100.0% in the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $630,000 after acquiring an additional 150,000 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.